Zur Personenübersicht
  • Studiengangsleiter

Prof. Dr. habil. Marcus Grimm

Professor und Studiengangsleiter für den Bachelorstudiengang Ernährungstherapie und -beratung am Campus Rheinland
E-Mail:
Telefon: +493657734070

Über mich
Über mich


Prof. Dr. habil. Marcus Grimm, geboren am 4.3.1976, ist seit dem 1.Oktober 2021 Professor und Studiengangsleiter für den Bachelorstudiengang Ernährungstherapie und -beratung am Campus Rheinland in Leverkusen der SRH Hochschule für Gesundheit.

 

Nach dem Abitur (Durchschnittsnote 1,0) studierte er gefördert durch die Studienstiftung des deutschen Volkes Biochemie an der Johann Wolfgang Goethe-Universität Frankfurt und forschte während seiner Diplomarbeit an der Atmungskette (Note sehr gut).

 

Nach dem Studium wechselte er zur Promotion an das Zentrum für Molekulare Biologie (ZMBH) der Ruprecht-Karls-Universität Heidelberg. Während seiner Promotion konnte er die bidirektionale Wechselwirkung zwischen der Alzheimer Erkrankung und der Lipidhomöostase nachweisen, die Forschungsergebnisse wurden unter anderem in viel zitierten Artikeln in internationalen hochrangigen Zeitschriften wie z.B. Nature Cell Biology veröffentlicht. Seine Doktorarbeit wurde mit dem Prädikat summa cum laude ausgezeichnet.


Während seiner Promotion absolvierte er an der Allfinanzakademie in Kooperation mit der University of Wales den Master of Business Administration (MBA) als Fernstudium und wechselte nach der Promotion zur Universität des Saarlandes. Hier nahm er an mehreren multizentrischen EU-geförderten Studien zur Prävention der Alzheimer Erkrankung teil und habilitierte in diesem Bereich an der medizinischen Fakultät. Seine Forschungsarbeit wurde 2010 mit dem Forschungspreis ausgezeichnet. Während seiner Habilitation etablierte er ein molekular- und zellbiologisches Forschungslabor, das als zusätzlichen Schwerpunkt Analyse von Fetten betreibt. Diese Tätigkeit wird von ihm auch weiter mit Übernahme der Professur ausgeübt, so dass das Labor als Teil des Deutschen Instituts für Demenzprävention interessierten Studenten in Kooperation zur Verfügung steht.


Neben seinem Schwerpunkt in der Forschung und Hochschullehre ist er beratend in der Ernährungsberatung und Therapie tätig und an der Gründung eines Ernährungsberatungszentrums beteiligt.


Privat entspannt Prof. Grimm bei seinen Bienenvölkern und seiner kleinen Schafsherde und ist gerne mit seinen Hunden in der Natur unterwegs.

Auszug
An diesen Publikationen habe ich mitgewirkt

Oktober 2021
Publikationen Prof. Dr. habil. Marcus Grimm

Stand: Oktober 2021

h-index:36 (google scholar)

Gesamtzitationen > 3500 (google scholar)

 

  1. Originalarbeiten / research articles
  2. Übersichtsarbeiten / reviews
  3. Buchartikel
  4. Patente

 

 

  1. Originalarbeiten / research articles:

 

Mett J, Lauer AA, Janitschke D, Griebsch LV, Theiss EL, Grimm HS, Koivisto H, Tanila H, Hartmann T, Grimm MOW

Medium-chain length fatty acids enhance Ab degradation by affecting Insulin-degrading enzyme

Cells 10, 2941, 2021

 

Kurokin I, Lauer AA, Janitschke D, Winkler J, Theiss EL, Griebsch LV, Pilz SM, Matschke V, van der Laan M, Grimm HS, Hartmann T, Grimm MOW

Targeted Lipidomics of Mitochondria in a Cellular Alzheimer’s Disease Model
Biomedicines 9 (8), 1062 2021


Lauer AA, Janitschke D, dos Santos Guilherme M, Nguyen VTT, Bachmann CM, Qiao S, Schrul B, Boehm U, Grimm HS, Hartmann T, Endres K, Grimm MOW

Shotgun lipidomics of liver and brain tissue of Alzheimer’s disease model mice treated with acitretin
Scientific Reports 11 (1), 1-19 1 2021

 

Rosenberg A, Solomon A, Soininen H, Visser PJ, Blennow K, Hartmann T, Kivipelto M, LipiDiDiet clinical study group (Grimm MOW)

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial

Alzheimer’s Research and Therapy, Mar 25; 13(1):64, 2021


Ramesh G, Jarzembowski L, Schwarz Y, Poth V, Konrad M, Knapp ML, Schwär G, Lauer AA, Grimm MOW, Alansary D, Bruns D, Niemeyer BA

A short isoform of STIM1 confers frequency-dependent synaptic enhancement
Cell Reports 34 (11), 108844 1 2021


Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T, LipiDiDiet Clinical study group (Grimm MOW)

36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
Alzheimer's & Dementia 17 (1), 29 19 2021


Ramesh G, Jarzembowksi L, Schwarz Y, Konrad M, Poth V, Schwaer G, Lauer AA, Grimm MOW, Alansary D, Bruns D, Niemeyer BA

Short novel STIM1B uncovers a mechanism of synaptic enhancement
Available at SSRN 3707638 2 2021


Janitschke D, Lauer AA, Bachmann CM, Seyfried M, Grimm HS, Hartmann T, Grimm MOW

Unique Role of Caffeine Compared to Other Methylxanthines (Theobromine, Theophyline, Pentoxifylline, Propentofylline) in Regulation of AD Relevant Genes in Neuroblastoma SH-SY5Y Wild Type Cells

International Journal of Molecular Sciences, 2020 Dec; 21(23): 9015

 

Lauer AA, Mett J, Janitschke D, Thiel A, Stahlmann CP, Bachmann CM, Ritzmann F, Schrul B, Müller UC, Stein R, Riemenschneider M, Grimm HS, Hartmann T, Grimm MOW

Regulatory feedback cycle of the insulin-degrading enzyme and the amyloid precursor protein intracellular domain: Implications for Alzheimer’s disease

Aging Cell, 2020 Nov; 19(11): e13264

 

Grimm MOW, Blümel T, Lauer AA, Janitschke D, Stahlmann C, Mett J, Haupenthal VJ, Miederer AM, Niemeyer BA, Grimm HS, Hartmann T

The impact of capsaicinoids on APP processing in Alzheimer’s disease in SH-SY5Y cells

Scientific Reports, 2020; 10: 9164

 

Gadomsky L, dos Santos Guilherme M, Winkler J, van der Kooij MA, Hartmann T, Grimm M, Endres K

Elevated Testosterone Level and Urine Scent Marking in Male 5xFAD Alzheimer Model Mice

Current Alzheimer Research, 2020; 17(1): 80-92

 

Janitschke D, Nelke C, Lauer AA, Regner L, Winkler J, Thiel A, Grimm HS, Hartmann T, Grimm MOW

Effect of Caffeine and Other Methylxanthines on Ab-Homeostasis in SH-SY5Y Cells

Biomolecules. 2019 Nov; 9(11): 689

 

Grimm MOW, Lauer AA, Grösgen S, Thiel A, Lehmann J, Winkler J, Janitschke D, Herr C, Beisswenger C, Bals R, Grimm HS, Hartmann T

Profiling of Alzheimer’s disease related genes in mild to moderate vitamin D hypovitaminosis

The Journal of Nutritional Biochemistry, 2019, May; 67:123-137

 

Reinkardt S, Schuck F, Stoye N, Hartmann T, Grimm MOW, Pflugfelder G, Endres K

Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer’s disease

Cellular and Molecular Life Sciences, 2019 Mar; 76(5): 1005-1025

 

Verheijen BM, Stevens JAA, Gentier RJG, van’t Hekke CD, van den Hove DLA, Hermes DJHP, Steinbusch HWM, Ruijter JM, Grimm MOW, Haupenthal VJ, Annaert W, Hartmann T, van Leeuwen FW

Paradoxical effects of mutant ubiquitin on Ab plaque formation in an Alzheimer mouse model

Neurobiology of Aging, 2018 Dec; 72:62-71

 

Soininen H, Solomon A, Visser PJ, Hendrix SB, Kaj Blennow, Kivipelto M, Hartmann T, LipiDiDiet clinical study group (Grimm MO co-author, part of the Lipididiet study group)

24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial

Lancet Neurology, 2017 Dec; 16(12): 965–975

 

Grimm MOW, Thiel A, Lauer AA, Winkler J, Lehmann J, Regner L, Nelke C, Janitschke D, Benoist C, Streidenberger O, Stötzel H, Endres K, Herr C, Beisswenger C, Grimm HS, Bals R, Lammert F, Hartmann T

Vitamin D and Its Analogues Decrease Amyloid-b (Ab) Formation and Increase Ab-degradation

International Journal of Molecular Sciences, 2017 Dec; 18(12): 2764

 

Brandscheid C, Schuck F, Reinhardt S, Schäfer KH, Pietrzik CU, Grimm M, Hartmann T, Schwiertz A, Endres K.

Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model.

Journal of Alzheimers Disease, 2017;56(2):775-788

 

Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Blümel T, Stötzel H, Grimm HS, Hartmann T.

Eicosapentaenoic acid and docosahexaenoic acid increase the degradation of amyloid-β by affecting insulin-degrading enzyme.

Biochemistry and Cell Biology, 2016 Dec;94(6):534-542

 

Grimm MO, Regner L, Mett J, Stahlmann CP, Schorr P, Nelke C, Streidenberger O, Stoetzel H, Winkler J, Zaidan SR, Thiel A, Endres K, Grimm HS, Volmer DA, Hartmann T.

Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for Alzheimer's Disease.

International Journal of Molecular Sciences, 2016 Oct 29;17(11)

 

Wittmann A*, Grimm MO*, Scherthan H, Horsch M, Beckers J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Ford SJ, Burton NC, Razansky D, Trümbach D, Aichler M, Walch AK, Calzada-Wack J, Neff F, Wurst W, Hartmann T, Floss T. * equal contribution

Sphingomyelin Synthase 1 Is Essential for Male Fertility in Mice.

PLoS One 2016, Oct 27;11(10)

 

Endres K, Reinhardt S, Geladaris A, Knies J, Grimm M, Hartmann T, Schmitt U.

Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice.

BMC Neuroscience, 2016 Jul 4;17(1):44

 

Reinhardt S, Grimm MO, Stahlmann C, Hartmann T, Shudo K, Tomita T, Endres K.

Rescue of Hypovitaminosis A Induces Non-Amyloidogenic Amyloid Precursor Protein (APP) Processing.

Current Alzheimer Research, 2016;13(11):1277-1289

 

Grimm MO, Haupenthal VJ, Mett J, Stahlmann CP, Blümel T, Mylonas NT, Endres K, Grimm HS, Hartmann T.

Oxidized Docosahexaenoic Acid Species and Lipid Peroxidation Products Increase Amyloidogenic Amyloid Precursor Protein Processing.

Neurodegenerative Diseases, 2016;16(1-2):44-54.

 

Blacher E, Dadali T, Bespalko A, Haupenthal VJ, Grimm MO, Hartmann T, Lund FE, Stein R, Levy A.

Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model.

Annals of Neurology, 2015 Jul;78(1):88-103. doi: 10.1002/ana.24425. Epub 2015 May 25.

 

Grimm MO, Mett J, Stahlmann CP, Grösgen S, Haupenthal VJ, Blümel T, Hundsdörfer B, Zimmer VC, Mylonas NT, Tanila H, Müller U, Grimm HS, Hartmann T.

APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression.

Frontiers in Aging Neuroscience, 2015 May 19;7:77

 

Grimm MOW, Stahlmann CP, Mett J, Haupenthal VJ, Zimmer VC, Lehmann J, Hundsdörfer B, Endres, K, Grimm HS, Hartmann T.

Vitamin E: Curse or benefit in Alzheimer’s disease? A systematic investigation of the impact of a-, g- and d-Tocopherol on Ab generation and degradation in neuroblastoma cell.

Journal of Nutrition, Health & Aging, 2015, 19(6):646-56

 

Karaca I, Tamboli IY, Glebov K, Richter J, Fell LH, Grimm MO, Haupenthal VJ, Hartmann T, Gräler MH, van Echten-Deckert G, Walter J.

Deficiency of Sphingosine-1-phosphate Lyase Impairs Lysosomal Metabolism of the Amyloid Precursor Protein.

The Journal of Biological Chemistry, 2014, 289(24): 16761-16772

 

Koivisto H, Grimm MO, Rothhaar TL, Berkecz R, Lütjohann D D, Giniatullina R, Takalo M, Miettinen PO, Lahtinen HM, Giniatullin R, Penke B, Janáky T, Broersen LM, Hartmann T, Tanila H.

Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition.

The Journal of Nutritional Biochemistry, 2014, 25(2):157-69

 

Reinhardt S, Schuck F, Grösgen S, Riemenschneider M, Hartmann T, Postina R, Grimm M, Endres K.

Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease.

FASEB Journal, 2014, 28(2):978-97

 

Grimm MOW, Hundsdörfer B, Grösgen S, Mett J, Zimmer VC, Stahlmann CP, Haupenthal VJ, Rothhaar TL, Lehmann J, Pätzold A, Zinser EG, Tanila H, Shen J, Müller U, Grimm HS, Hartmann T.

PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer’s disease

Cellular Physiology and Biochemistry, 2014, 34(1): 92-110

 

Robinson A, Grösgen S, Mett J, Zimmer VC, Haupenthal VJ, Hundsdörfer B, Stahlmann CP, Slobodskoy Y, Müller UC, Hartmann T, Stein R, Grimm MO.

Upregulation of PGC-1α expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP.

Aging Cell, 2014, 13(2):263-72.

 

Grimm MO, Lehmann J, Mett J, Zimmer VC, Grösgen S, Stahlmann CP, Hundsdörfer B, Haupenthal VJ, Rothhaar TL, Herr C, Bals R, Grimm HS, Hartmann T.

Impact of Vitamin D on amyloid precursor protein processing and amyloid-β peptide degradation in Alzheimer's disease.

Neurodegenerative Diseases, 2014, 13(2-3):75-81.

 

Burg VK, Grimm HS, Rothhaar TL, Grösgen S, Hundsdörfer B, Haupenthal VJ, Zimmer VC, Mett J, Weingärtner O, Laufs U, Broersen LM, Tanila H, Vanmierlo T, Lütjohann D, Hartmann T, Grimm MO.

Plant sterols the better cholesterol in Alzheimer's disease? A mechanistical study.

The Journal of Neuroscience, 2013, 9;33(41):16072-87.

 

Grimm MO, Haupenthal VJ, Rothhaar TL, Zimmer VC, Grösgen S, Hundsdörfer B, Lehmann J, Grimm HS, Hartmann T.

Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer's Disease.

International Journal of Molecular Sciences, 2013, 14(3):5879-98.

 

Rothhaar TL, Grösgen S, Haupenthal VJ, Burg VK, Hundsdörfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO.

Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease.

The Scientific World Journal, 2012, 2012:141240.

 

Grimm MO, Zinser EG, Grösgen S, Hundsdörfer B, Rothhaar TL, Burg VK, Kaestner L, Bayer TA, Lipp P, Müller U, Grimm HS, Hartmann T.

Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer's disease pathology with ganglioside metabolism.

PLoS One, 2012, 7(3):e34095.

 

Grimm MO, Rothhaar TL, Grösgen S, Burg VK, Hundsdörfer B, Haupenthal VJ, Friess P, Kins S, Grimm HS, Hartmann T.

Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP).

The Journal of Nutritional Biochemistry, 2012, 23(10):1214-23.

 

Vanmierlo T, Weingärtner O, van der Pol S, Husche C, Kerksiek A, Friedrichs S, Sijbrands E, Steinbusch H, Grimm M, Hartmann T, Laufs U, Böhm M, de Vries HE, Mulder M, Lütjohann D.

Dietary intake of plant sterols stably increases plant sterol levels in the murine brain.

Journal of Lipid Research, 2012, 53(4):726-35.

 

Grimm MO, Grösgen S, Riemenschneider M, Tanila H, Grimm H, Hartmann T.

From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry.

Journal of Chromatography A, 2011, 1218(42):7713-22.

 

Grimm MO, Grösgen S, Rothhaar TL, Burg VK, Hundsdörfer B, Haupenthal VJ, Friess P, Müller U, Fassbender K, Riemenschneider M, Grimm HS, Hartmann T.

Intracellular APP Domain Regulates Serine-Palmitoyl-CoA Transferase Expression and Is Affected in Alzheimer's Disease.

International Journal of Alzheimers Disease, 2011, 2011:695413.

 

Grimm MO, Kuchenbecker J, Grösgen S, Burg VK, Hundsdörfer B, Rothhaar TL, Friess P, de Wilde MC, Broersen LM, Penke B, Péter M, Vígh L, Grimm HS, Hartmann T.

Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms.

The Journal of Biological Chemistry, 2011, 286(16):14028-39.

 

Grimm MO, Kuchenbecker J, Rothhaar TL, Grösgen S, Hundsdörfer B, Burg VK, Friess P, Müller U, Grimm HS, Riemenschneider M, Hartmann T.

Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease.

Journal of Neurochemistry, 2011, 116(5):916-25.

 

Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rübe CE, Menger MD, Fassbender K.

Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology.

Brain, 2011, 134(Pt 1):278-92.

 

Schäfer KH, Braun A, Semar S, Letiembre M, Klotz M, Klein JC, Grimm MO,       Micci MA, Taglialatela G, Liu Y, Fassbender K, Hartmann T

Alzheimers Disease affects the Entiric Nervous System

Gastroenterology, 2011, vol. 140, 5: S54-S54

 

Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C.

Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels.

The Journal of Biological Chemistry, 2008, 283(17):11302-11.

 

Grimm MO, Grimm HS, Pätzold AJ, Zinser EG, Halonen R, Duering M, Tschäpe JA, De Strooper B, Müller U, Shen J, Hartmann T.

Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin.

Nature Cell Biology, 2005, 7(11):1118-23.

 

Duering M, Grimm MO, Grimm HS, Schröder J, Hartmann T.

Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42.

Neurobiology of Aging, 2005, 26(6):785-8.

 

Grziwa B, Grimm MO, Masters CL, Beyreuther K, Hartmann T, Lichtenthaler SF.

The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted.

The Journal of Biological Chemistry, 2003, 278(9):6803-8.

 

Grimm MO, Tomic I, Hartmann T.

Potential external source of A beta in biological samples.

Nature Cell Biology, 2002, 4(7):E164-5;

 

  1. Übersichtsarbeiten / Reviews:

Janitschke D, Lauer AA, Bachmann CM, Grimm HS, Hartmann T, Grimm MOW

Methylxanthines and neurodegenerative diseases: an update

Nutrients 13 (3), 803 1 2021

 

Grimm MO, Michaelson D, Hartmann T

Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Journal of Lipid Research, 2017 Nov; 58(11): 2083–2101

 

Grimm MO, Mett J, Grimm HS, Hartmann T.

APP Function and Lipids: A Bidirectional Link.

Frontiers in Molecular Neuroscience. 2017 Mar 10;10:63

 

Grimm MO, Mett J, Hartmann T.

The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease.

International Journal of Molecular Sciences, 2016 Oct 26;17(11)

 

Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T.

The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.

BioMed Research International, 2013, 2013:814390.

 

Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T.

Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease.

Frontiers in Aging Neuroscience, 2013, 5:98.

 

Grimm MO, Rothhaar TL, Hartmann T.

The role of APP proteolytic processing in lipid metabolism.

Experimental Brain Research, 2012, 217(3-4):365-75.

 

Grimm MOW, Hartmann T

Recent Understanding of the Molecular Mechanisms of Alzheimer’s Disease

Journal of Addiction Research and Therapy, 2012, S5

 

Grösgen S, Grimm MO, Friess P, Hartmann T.

Role of amyloid beta in lipid homeostasis.

Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 2010, 1801(8):966-74.

 

Hartmann T, Kuchenbecker J, Grimm MO.

Alzheimer's disease: the lipid connection.

Journal of Neurochemistry, 2007, 103 Suppl 1:159-70.

 

Grimm MO, Grimm HS, Hartmann T.

Amyloid beta as a regulator of lipid homeostasis.

Trends in Molecular Medicine, 2007, 13(8):337-44.

 

Zinser EG, Hartmann T, Grimm MO.

Amyloid beta-protein and lipid metabolism.

Biochimica et Biophysicy Acta (Biomembranes), 2007, 1768(8):1991-2001.

 

Hartmann T, Fassbender K, Grimm MO (2007). 

Alzheimer´s disease prevention - The emerging role of lipids and diet

OCL - Oleagineux Corps Gras Lipides Vol.14. 

 

Grimm MO, Tschäpe JA, Grimm HS, Zinser EG, Hartmann T.

Altered membrane fluidity and lipid raft composition in presenilin-deficient cells.

Acta Neurologica Scandinavica, 2006, 185:27-32.

 

  1. Buchartikel:

Lauer AA, Janitschke D, Hartmann T, Grimm HS, Grimm MOW (2019)

The Effects of Vitamin D Deficiency on Neurodegenerative Diseases

IntechOpen, DOI: 10.5772/intechopen.89160

 

Mett J, Hartmann T, Grimm MO (2014)

The effects of glycerophospholipids and fatty acids on APP processing: Implications for Alzheimer’s disease

Handbook of Lipids in Human Function: Fatty Acids, Chapter: Chapter 13, Publisher: AOCS Press Elsevier, Editors: Ronald Ross Watson, Fabien De Meester, pp.377-423

 

Grimm MO, Grösgen S, Hartmann T (2009)

Link between Gangliosides, Sphingolipids and Alzheimer’s Disease 

9th International Conference on Alzheimer´s and Parkinson´s Disease AD/PD. (eds. A. Fisher & I. Hanin), 317-320. (Medimond International Proceedings, Praque, Czech Republic) 

 

Tschaepe JA*, Grimm MO*, Grimm HS, Hartmann T (2008) (*equal contribution)

Cholesterol and A beta production: Methods for analysis of altered cholesterol de novo synthesis,

Advances in Alzheimer´s and Parkinson´s disease. Insights, Progress, and Perspectives, 221-230. 

 

Grimm MO, Kuchenbecker J, Zinser EG, Hartmann T (2007) 

Plasmalogens and APP-Processing: Method for the Analysis of Altered Plasmalogen Homeostasis,

8th International Conference on Alzheimer´s and Parkinson´s Disease AD/PD. (eds. A. Fisher & I. Hanin), 312-315. (Medimond International Proceedings, Salzburg, Austria) 

 

Grimm MO, Zinser EG, Grimm H, Wilk S, Müller U, Hartmann T

Link between APP-processing, Alzheimer disease and Glycosphingolipid metabolism

2nd ISN Special Neurochemistry Conference on Neural Glycoproteins and Glycolipids, 2006, Vol.99 (Antigua, West Indies)

 

Grimm MOW, Paetzold AJ, Grimm HS, Zinser EG, Ruppert T, Hartmann T (2005) 

Linking Alzheimer's disease, ß-Amyloid, and Lipids: a technical approach, CRC Press (Boca Raton, Florida)

 

  1. Patente:


T Hartmann, MOW Grimm, T Floss, A Wittmann

Omega-3 and/or omega-6 fatty acid (s) in impaired sphingolipid metabolism
US Patent 10,744,108 2020

 

T Hartmann, MOW Grimm, T Floss, A Wittmann (all inventors contributed equally)

Application of omega-3 and / or omega-6 fatty acid(s) 

Patent Nummer: DE 102015109352 A1

 

 

MOW Grimm, T Hartmann, P Frieß-Javorkova, U Laufs, O Weingärtner

Stigmasterol for the treatment of alzheimer's disease 

Patent Nummer: WO 2010104375 A1